It has been suggested that an abundance of phosphorylated PARP1 may predict tumor resistance and that the combination of c-Met and PARP inhibitors may benefit patients whose tumors demonstrate high levels of c-Met expression [82]. The gene discussed is PARP1; the disease is neoplasm.